Latest Chrysos (ASX:C79) News

Gold explorers and small-cap tech names drove the biggest share price swings this week, while one healthcare stock sank after a deeply discounted funding move. Deals, drill hits and fresh financing dominated trading across the ASX.

Gold stories drove the week, but the biggest jumps came from drill hits and project studies that gave investors a reason to chase smaller names. At the larger end, merger activity and fresh funding kept attention on producers that want to get bigger, faster.

Small-cap tech buyers chased AI, defence and digital infrastructure this week, while a few names gave back gains after reopening jumps. The biggest moves came from contract wins, fresh capital and clear signs that products are getting closer to real sales.

Chrysos Corporation has hit a new milestone with over one million samples processed monthly, driven by expanding lease agreements and deployments of its PhotonAssay technology. The company remains on track for FY26 revenue and EBITDA guidance amid accelerating global growth.

Deal headlines and big drill hits shared the stage with a brutal sell-off in a handful of tiny raisings. The week’s biggest winners were backed by clear news; the biggest losers showed what happens when buyers vanish after a halt.

Small caps stole the spotlight, with a handful of stocks doubling on deal news and early-stage project updates. Large miners were steadier, but even they couldn’t fully escape the week’s sharp gap moves.

Chrysos Corporation Limited reported a robust 1H FY26 with revenue up 49% and EBITDA soaring 152%, driven by expanding adoption of its PhotonAssay technology and strategic global deployments.

CSIRO has sold about half its shares in Chrysos Corporation through a block trade, reducing its stake by roughly 9%, yet remains a committed substantial shareholder with a six-month escrow on its retained shares.

Chrysos Corporation reports nearly one million monthly PhotonAssay samples and reiterates strong FY26 revenue guidance, while unveiling next-gen assay technologies and global expansion plans.

Chrysos Corporation reported record FY25 financial results, driven by strong global demand for its innovative PhotonAssay™ technology. The company expanded its footprint, enhanced sustainability credentials, and strengthened governance, positioning itself for continued growth.

Chrysos Corporation reported robust FY25 results driven by record sample volumes and expanded global deployments of its PhotonAssay technology. The company reiterates strong FY26 guidance amid growing international partnerships.

Chrysos Corporation has confirmed its FY25 financial results, reporting $66.1 million in revenue and $16.1 million EBITDA, while reinforcing its commitment to advancing its PhotonAssay technology for mining analysis.